Table 1.
Demographics and Clinical Characteristics of Patients Treated with Warfarin for VTE among Parenteral Anticoagulant Users and Nonusers
| Characteristics | Parenteral anticoagulant users | Parenteral anticoagulant nonusers |
| Total patients in the cohort, N (%) | 4403 (75.7) | 1417 (24.3) |
| Mean age, yrs (SD) | 50 (10)a | 52.2 (9.7)a |
| Female, N (%) | 1951 (44.3) | 665 (46.9) |
| PE as index VTE event, N (%) | 420 (9.5)a | 247 (17.4)a |
| Time to warfarin initiation from index VTE claim | ||
| Mean (SD), days | 9.8 (9)a | 13.1 (8.5)a |
| Median, days | 5 | 11 |
| Time to warfarin initiation relative to parenteral anticoagulation therapy initiation | ||
| Before starting parenteral agent, N (%) | 61 (1.39) | — |
| Same day as initiating parenteral agent, N (%) | 1094 (24.85) | — |
| Within 3 days of starting parenteral agent, N (%) | 960 (21.8) | — |
| >3 days after starting parenteral agent, N (%) | 2288 (51.96) | — |
| Baseline Elixhauser Comorbidity Index score, mean (SD) | 1.4 (1.6)a | 2.1 (2.1)a |
| Patients with cancer, N (%) | 379 (8.6) | 134 (9.5) |
a
Significant difference, P <.01.
PE indicates pulmonary embolism; SD, standard deviation; VTE, venous thromboembolism.